Carisma Therapeutics Inc. — Director's Dealing 2020

Feb 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sesen Bio, Inc. (SESN)
CIK: 0001485003
Period of Report: 2020-02-13

Reporting Person: Sullivan Mark (General Counsel & Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-13	Employee Stock Option (Right to Buy)	$0.8911	A	260000	Acquired	2030-02-13	Common Stock (260000.0)	Direct

Footnotes

F1: On February 13, 2020, the reporting person was awarded options to purchase 260,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date.